Protagonist (PTGX) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
434.4M
Operating Income
252.8M
58.20%
Net Income
275.2M
63.34%
EPS (Diluted)
$4.23
Balance Sheet Metrics
Total Assets
744.7M
Total Liabilities
69.4M
Shareholders Equity
675.3M
Debt to Equity
0.10
Cash Flow Metrics
Operating Cash Flow
189.8M
Free Cash Flow
182.8M
Revenue & Profitability Trend
Protagonist Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 434.4M | 60.0M | 26.6M | 27.4M | 28.6M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 181.6M | 153.7M | 158.0M | 153.2M | 93.1M |
| Operating Income | 252.8M | -93.7M | -131.4M | -125.8M | -64.5M |
| Pre-tax Income | 279.4M | -79.0M | -127.4M | -125.6M | -64.8M |
| Income Tax | 4.2M | - | 0 | 0 | 1.3M |
| Net Income | 275.2M | -79.0M | -127.4M | -125.6M | -66.2M |
| EPS (Diluted) | $4.23 | -$1.39 | -$2.60 | -$2.71 | -$1.92 |
Income Statement Trend
Protagonist Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 591.6M | 355.6M | 243.1M | 340.7M | 315.6M |
| Non-Current Assets | 153.1M | 2.4M | 4.9M | 7.0M | 8.9M |
| Total Assets | 744.7M | 358.0M | 247.9M | 347.7M | 324.5M |
| Liabilities | |||||
| Current Liabilities | 47.4M | 21.3M | 31.2M | 44.0M | 40.2M |
| Non-Current Liabilities | 22.0M | 0 | 1.1M | 3.7M | 4.6M |
| Total Liabilities | 69.4M | 21.3M | 32.3M | 47.7M | 44.9M |
| Equity | |||||
| Total Shareholders Equity | 675.3M | 336.7M | 215.6M | 300.0M | 279.6M |
Balance Sheet Composition
Protagonist Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 275.2M | -79.0M | -127.4M | -125.6M | -66.2M |
| Operating Cash Flow | 189.8M | -61.8M | -97.8M | -123.7M | -79.2M |
| Investing Activities | |||||
| Capital Expenditures | -1.4M | -609.0K | -795.0K | -1.1M | -471.0K |
| Investing Cash Flow | -299.5M | -39.3M | 91.5M | -15.9M | -91.0M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -600.0K | 131.3M | 14.4M | 123.6M | 244.8M |
| Free Cash Flow | 182.8M | -70.8M | -108.9M | -109.0M | -73.0M |
Cash Flow Trend
Protagonist Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
68.81
Forward P/E
-37.53
Price to Book
4.82
Price to Sales
16.01
PEG Ratio
-37.53
Profitability Ratios
Profit Margin
27.04%
Operating Margin
-68.18%
Return on Equity
8.99%
Return on Assets
2.48%
Financial Health
Current Ratio
17.26
Debt to Equity
1.65
Beta
2.24
Per Share Data
EPS (TTM)
$0.78
Book Value per Share
$11.13
Revenue per Share
$3.35
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ptgx | 3.3B | 68.81 | 4.82 | 8.99% | 27.04% | 1.65 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.